Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Rayson · SciRah

Researcher profile · Semantic Scholar

D. Rayson

Share profile

D. Rayson — researcher profile on SciRah

h-index: 34
Works: 172
Citations: 4,171

Most-cited papers

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
K. Broglio, M. Quintana, M. Foster, Melissa Olinger +10 more
2016JAMA Oncology327 citations Open access
Semantic Scholar
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.
E. Grunfeld, J. Julian, G. Pond, E. Maunsell +16 more
2011Journal of Clinical Oncology311 citations Open access
Semantic Scholar
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
S. Virani, S. Dent, C. Brezden-Masley, B. Clarke +21 more
2016Canadian Journal of Cardiology222 citations Open access
Semantic Scholar
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.
J. Mackey, R. Kerbel, K. Gelmon, D. McLeod +7 more
2012Cancer Treatment Reviews111 citations
Semantic Scholar
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
T. Bachelot, E. Ciruelos, A. Schneeweiss, F. Puglisi +288 more
2019Annals of Oncology108 citations Open access
Semantic Scholar
Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.
S. Singh, S. Asa, C. Dey, H. Kennecke +12 more
2016Cancer Treatment Reviews101 citations
Semantic Scholar
Interfaces across the cancer continuum offer opportunities to improve the process of care.
S. Taplin, S. Clauser, A. Rodgers, Erica S. Breslau +1 more
2010Journal of the National Cancer Institute. Monographs92 citations Open access
Semantic Scholar
Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group
Siddharth Singh, C. Dey, H. Kennecke, W. Kocha +9 more
2014Annals of Surgical Oncology91 citations
Semantic Scholar
Compression garments versus compression bandaging in decongestive lymphatic therapy for breast cancer-related lymphedema: a randomized controlled trial
M. King, A. Deveaux, H. White, D. Rayson
2012Supportive Care in Cancer81 citations
Semantic Scholar
Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients
A. Drucker, Evelyn Teh, Ripsik Kostyleva, D. Rayson +2 more
2020PLoS ONE62 citations Open access
Semantic Scholar
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
N. Lamond, C. Skedgel, D. Rayson, L. Lethbridge +1 more
2012Breast Cancer Research and Treatment57 citations
Semantic Scholar
Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.
D. Rayson, J. Payne, M. Abdolell, P. Barnes +5 more
2011Clinical Breast Cancer53 citations
Semantic Scholar
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
D. Rayson, S. Lupichuk, K. Potvin, S. Dent +16 more
2016Breast Cancer Research and Treatment50 citations
Semantic Scholar
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis
T. Younis, D. Rayson, K. Thompson
2012Supportive Care in Cancer48 citations
Semantic Scholar
Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis.
D. Rayson, R. Urquhart, M. Cox, E. Grunfeld +1 more
2012Journal of Oncology Practice48 citations Open access
Semantic Scholar
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
M. Clemons, B. Cochrane, G. Pond, N. Califaretti +9 more
2014Breast Cancer Research and Treatment47 citations
Semantic Scholar
Immunohistochemical Expression and Prognostic Value of ER, PR and HER2/neu in Pancreatic and Small Intestinal Neuroendocrine Tumors
T. Arnason, Heidi L. Sapp, Penelope J Barnes, M. Drewniak +2 more
2011Neuroendocrinology40 citations
Semantic Scholar
The coordination of primary and oncology specialty care at the end of life.
P. Han, D. Rayson
2010Journal of the National Cancer Institute. Monographs40 citations Open access
Semantic Scholar
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.
D. Rayson, Thomas M. Suter, C. Jackisch, S. van der Vegt +14 more
2012Annals of Oncology39 citations Open access
Semantic Scholar
Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors.
T. Arnason, Heidi L. Sapp, D. Rayson, Penelope J Barnes +3 more
2011Archives of Pathology & Laboratory Medicine39 citations Open access
Semantic Scholar
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
J. Henning, C. Brezden-Masley, K. Gelmon, S. Chia +4 more
2023Current Oncology37 citations Open access
Semantic Scholar
The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.
T. Younis, D. Rayson, C. Skedgel
2011Current Oncology32 citations Open access
Semantic Scholar
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
J. Kotsopoulos, J. Gronwald, T. Huzarski, A. Aeilts +40 more
2023Breast Cancer Research and Treatment28 citations Open access
Semantic Scholar
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
C. Simmons, D. Rayson, A. Joy, J. Henning +5 more
2022Therapeutic Advances in Medical Oncology24 citations Open access
Semantic Scholar
Improving Nodal Harvest in Colorectal Cancer: So What?
G. Porter, R. Urquhart, Jingyu Bu, P. Johnson +2 more
2012Annals of Surgical Oncology24 citations
Semantic Scholar
The role of scientific evidence in decisions to adopt complex innovations in cancer care settings: a multiple case study in Nova Scotia, Canada
R. Urquhart, C. Kendell, L. Geldenhuys, A. Ross +6 more
2019Implementation Science23 citations Open access
Semantic Scholar
Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy.
A. Jeyakumar, Jillian C Dipenta, S. Snow, D. Rayson +3 more
2012Clinical Breast Cancer23 citations
Semantic Scholar
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
S. Verma, A. Joy, D. Rayson, D. McLeod +3 more
2013The Oncologist20 citations Open access
Semantic Scholar
Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors.
E. Grunfeld, M. Levine, J. Julian, G. Pond +14 more
2011Journal of Clinical Oncology17 citations
Semantic Scholar
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
K. Pritchard, S. Chia, C. Simmons, D. McLeod +3 more
2017The Oncologist15 citations Open access
Semantic Scholar
Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression‐Free Survival on First‐Line Therapy Predicts Overall Survival Impact
D. Rayson, S. Lutes, G. Walsh, M. Sellon +5 more
2014The Breast Journal14 citations
Semantic Scholar
Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?
C. Skedgel, D. Rayson, T. Younis
2013Annals of Oncology14 citations Open access
Semantic Scholar
To The Last Drop.
D. Rayson
2017Journal of Clinical Oncology13 citations
Semantic Scholar
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment
H. Assi, J. Murray, L. Boyle, D. Rayson
2014Supportive Care in Cancer13 citations
Semantic Scholar
The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations
S. Narod, K. Metcalfe, A. Finch, An-Wen Chan +30 more
2024Hereditary Cancer in Clinical Practice12 citations Open access
Semantic Scholar
Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
T. Younis, D. Rayson, S. Jovanović, C. Skedgel
2016Breast Cancer Research and Treatment12 citations Open access
Semantic Scholar
Primary large cell neuroendocrine carcinoma of the skin: An under‐recognized entity and a mimic of metastatic disease
I. M. Lano, D. Rayson, T. Arnason, N. Walsh
2018Journal of cutaneous pathology11 citations
Semantic Scholar
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.
M. Yan, C. Ho, E. Winquist, D. Jonker +5 more
2016Clinical colorectal cancer10 citations
Semantic Scholar
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
C. Skedgel, D. Rayson, T. Younis
2015Supportive Care in Cancer10 citations
Semantic Scholar
On denying denial.
D. Rayson
2013Journal of Clinical Oncology10 citations
Semantic Scholar
Impact of Detection Method and Age on Survival Outcomes in Triple‐Negative Breast Cancer: A Population‐Based Cohort Analysis
D. Rayson, J. Payne, J. Michael, K. Tsuruda +2 more
2018Clinical Breast Cancer9 citations
Semantic Scholar
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
D. Rayson, S. Gandhi, A. Joy, C. Brezden-Masley +4 more
2022Current Oncology8 citations Open access
Semantic Scholar
Independent primary cutaneous and mammary apocrine carcinomas with neuroendocrine differentiation: Report of a case and literature review
R. DeCoste, Michael D. Carter, Penelope J Barnes, A. Andea +3 more
2021Journal of cutaneous pathology8 citations Open access
Semantic Scholar
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
N. Stjepanovic, J. Lubiński, P. Møller, Susan Randall Armel +54 more
2021Breast Cancer Research and Treatment8 citations
Semantic Scholar
Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study.
R. Urquhart, C. Kendell, G. Buduhan, D. Rayson +4 more
2016CMAJ Open8 citations Open access
Semantic Scholar
Quantifying limitations in chemotherapy data in administrative health databases: implications for measuring the quality of colorectal cancer care.
R. Urquhart, D. Rayson, G. Porter, E. Grunfeld
2011Healthcare Policy | Politiques de Santé8 citations Open access
Semantic Scholar
ACTH‐Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature
A. Mokhtar, T. Arnason, D. Gaston, Weei-Yuarn Huang +5 more
2019Clinical colorectal cancer7 citations
Semantic Scholar
A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).
D. Rayson, S. Lupichuk, S. Chia, K. Potvin +12 more
20127 citations
Semantic Scholar
Investigations for patients with early-stage breast cancer: oversetting the stage
D. Rayson, G. Porter
2015Canadian Medical Association Journal4 citations Open access
Semantic Scholar
Terry Fox: Canadian cancer research activist whose "Marathon of Hope" inspired millions.
D. Steensma, D. Rayson, M. Shampo, R. Kyle
2014Mayo Clinic proceedings4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Younis×9
Invite
T. Younis — researcher profile on SciRah
S. Chia×7
Invite
S. Chia — researcher profile on SciRah
A. Joy×7
Invite
A. Joy — researcher profile on SciRah
G. Porter×7
Invite
G. Porter — researcher profile on SciRah

C. Brezden-Masley

×6

Invite

C. Brezden-Masley — researcher profile on SciRah

Invite

S. Dent — researcher profile on SciRah

Invite

E. Grunfeld — researcher profile on SciRah

Invite

K. Gelmon — researcher profile on SciRah

K. Pritchard×5

Invite

K. Pritchard — researcher profile on SciRah

Invite

A. Robidoux — researcher profile on SciRah

Invite

C. Skedgel — researcher profile on SciRah

Invite

R. Urquhart — researcher profile on SciRah